subscribeSubscribe
Voydeya approved in the EU as add-on treatment to ravulizumab

Voydeya approved in the EU as add-on treatment to ravulizumab
PRESS RELEASE
23 Apr 2024
Share Share
AZ`s Alexion debuts short film highlighting NMOSD community

AZ`s Alexion debuts short film highlighting NMOSD community
Andrea Park FIERCE PHARMA
18 Apr 2024
Share Share
Onco360 Has Selected as the Sole National Specialty Pharmacy Partner for Voydeya

Onco360 Has Selected as the Sole National Specialty Pharmacy Partner for Voydeya
GLOBENEWSWIRE
08 Apr 2024
Share Share
FDA clears AZ’s new PNH therapy Voydeya

FDA clears AZ’s new PNH therapy Voydeya
PRESS RELEASE
01 Apr 2024
Share Share
FDA expands AZ`s Ultomiris to NMOSD after prior rejection

FDA expands AZ`s Ultomiris to NMOSD after prior rejection
FIERCE PHARMA
26 Mar 2024
Share Share
ULTOMIRIS approved in the US for the treatment of adults with NMOSD

ULTOMIRIS approved in the US for the treatment of adults with NMOSD
BUSINESSWIRE
25 Mar 2024
Share Share
Voydeya recommended for approval in the EU by CHMP

Voydeya recommended for approval in the EU by CHMP
PRESS RELEASE
26 Feb 2024
Share Share
Alexion Pharma`s Biologic Ultomiris (ravulizumab) Receives Approval in the U.S.

Alexion Pharma`s Biologic Ultomiris (ravulizumab) Receives Approval in the U.S.
FDA
08 Feb 2024
Share Share
PIII trial data showed danicopan as add-on to ULTOMIRIS sustained improvements

PIII trial data showed danicopan as add-on to ULTOMIRIS sustained improvements
BUSINESSWIRE
10 Dec 2023
Share Share
FDA Rejects AstraZeneca’s Ultomiris Label Expansion in NMOSD

FDA Rejects AstraZeneca’s Ultomiris Label Expansion in NMOSD
BIOSPACE
07 Sep 2023
Share Share